歡迎來到演算法、軟體和硬體三位一體的未來世界論文書籍站
國立中山大學 中國與亞太區域研究所 林文程所指導 梁碩文的 中國一帶一路政策的挑戰-以馬來西亞為例 （2021），提出Us mrl關鍵因素是什麼，來自於『一帶一路』倡議、習近平、美中角力、馬哈地、莫哈末·納吉·阿都拉薩。
而第二篇論文國立中興大學 獸醫學系暨研究所 周濟眾所指導 汪玉祉的 利用醯胺醇類協同作用及組合外排泵抑制劑有效對抗豬胸膜肺炎放線桿菌與敗血性巴氏桿菌 （2021），提出因為有 氟甲磺氯黴素、甲磺氯黴素、外排泵抑制劑、豬胸膜肺炎放線桿菌、與敗血性巴氏桿菌的重點而找出了 Us mrl的解答。
中國一帶一路政策的挑戰-以馬來西亞為例
為了解決Us mrl 的問題，作者梁碩文 這樣論述：
中國在 2013 年由國家主席習近平所倡議的『一帶一路』計劃，是個雄心壯志的大工程。一開始就受到歐美媒體的大肆質疑，舉凡參與國任何施工問題或是國內政局動盪，都會被媒體宣稱中國意圖控制該國，並且與『一帶一路』計劃推行畫上等號。馬來西亞是為東協（Association of Southeast Asian Nation, ASEAN）第一個響應『一帶一路』計劃的國家，唯參與以來又歷經了建國 61 年來第一次的政黨輪替，國內局勢波動不安。而『一帶一路』計劃之實施，也使得國內貪瀆不斷，掀起政壇與民間巨大的波浪。本研究以文獻分析法以及歷史研究法，經由三角戰略做為研究途徑，從中美角力之大格局切入，並聚焦
於馬來西亞與中國的國際互動，兩國攜手之『一帶一路』計劃的起源與現況，另外亦剖析所遭遇到之挑戰。經由研究之進行得到三項結論：一、『一帶一路』推行是為馬來西亞於外交結合經濟的傾中的表態；二、與國際媒體呈現落差的馬來西亞『一帶一路』計劃的實際；三、務實而不受拘束的外交身段，是馬國求得國家最大利益的手段，但結果卻是差強人意。
利用醯胺醇類協同作用及組合外排泵抑制劑有效對抗豬胸膜肺炎放線桿菌與敗血性巴氏桿菌
為了解決Us mrl 的問題，作者汪玉祉 這樣論述：
Antimicrobial resistance (AMR) not only continues to pose a threat to therapy of infectious disease but also presents a major challenge for global health concerns. To make the matter worse, new antibiotics are not being discovered at a fast enough rate to counter the development of bacterial resist
ance. In veterinary medicine, amphenicols have been extensively used as the drug of choice to treat bacteria associated with porcine respiratory disease complex, namely, Actinobacillus pleruopeumoniae and Pasteurella multocida, thereby leading to varying levels of amphenicol resistance. To re-empowe
r existing antibiotics, using a combination of two commercially available antibiotics in the same class; FF and TAP, or a combination of amphenicols with efflux pump inhibitors (EPIs) as adjuvant therapy were investigated against porcine A. pleruopeumoniae and P. multocida in the current study. In
the first study, the in vitro and in vivo efficacy of FF+TAP combination were evaluated. The in vitro results from the checkerboard assay and reconfirmation with time kill study in the representative isolates illustrated that the synergistic FF-TAP combination was a potential therapeutic option for
treatment of A. pleuropneumoniae and P. multocida infection. In vivo experiments in pigs demonstrated that FF and TAP combination at a ratio correlating to their MIC deductions was equally effective to their original recommended dosage. In the second study, the effects of five EPIs including Carbon
yl Cyanide Chlorophenylhydrazone (CCCP), omeprazole, Phenylalanine-arginine β-naphthylamide (PAβN), reserpine and verapamil, on their ability to enhance the in vitro antimicrobial activity of FF were preliminarily evaluated. The results indicated that CCCP demonstrated promising improvement of FF ac
tivity while PAβN showed some effect but at high concentrations. Both broth microdilution and time kill assay complementarily confirmed the effect of CCCP on the antimicrobial activity of FF. In addition, the beneficial effect between FF and CCCP was initially identified as through the antagonizatio
n of the FloR pump conferred by the floR gene. In the third study, the effect of CCCP on the in vitro FF and TAP antimicrobial activity by a larger number of isolates, the presence of the efflux pump gene, and the intra-bacterial concentration of FF were further investigated. The CCCP, at relatively
low concentrations, could prominently improve FF and TAP antimicrobial activity in a dose-dependent manner, as well as increasing the intracellular concentration of FF, possibly by inhibition of the FloR efflux pump. Collectively, these findings underline the importance of FloR efflux pump in the d
evelopment of amphenicol resistance in A. pleuropneumoniae and P. multocida. Taken together, our studies may provide potential therapeutic options using amphenicols synergism and amphenicols in combination with EPIs against amphenicol-resistant A. pleuropneumoniae and P. multocida.